BlackRock Investment Management’s Seres Therapeutics MCRB Stock Holding History

BlackRock Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$661K	Buy	3,337 +53	+2%	+$11.6K	﹤0.01%	2930
2016 Q3	$807K	Sell	3,284 -149	-4%	-$52.3K	﹤0.01%	2802
2016 Q2	$1.99M	Buy	3,433 +937	+38%	+$550K	﹤0.01%	2100
2016 Q1	$1.33M	Buy	2,496 +26	+1%	+$13.6K	﹤0.01%	2295
2015 Q4	$1.73M	Buy	2,470 +43	+2%	+$28.3K	﹤0.01%	2184
2015 Q3	$1.44M	Buy	2,427 +1,412	+139%	+$1.15M	﹤0.01%	2315
2015 Q2	$842K	Buy	+1,015	New	+$886K	﹤0.01%	2895

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock Investment Management's MCRB Position: Q4 2016 in Review

BlackRock Investment Management increased its Seres Therapeutics (MCRB) stake by 1.6% in Q4 2016, buying an estimated $11.6K and bringing the position to 3,337 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #2930.

BlackRock Investment Management first reported a position in MCRB in Q2 2015 and has held it in 7 quarters since. The position peaked at $1.99M in Q2 2016. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

BlackRock Investment Management held 3,337 shares of Seres Therapeutics worth $661K as of Q4 2016.
BlackRock Investment Management bought 53 Seres Therapeutics shares in Q4 2016, an estimated $11.6K.
Seres Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2930 holding.
BlackRock Investment Management first reported a position in Seres Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's Seres Therapeutics position peaked at $1.99M in Q2 2016.
89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.